注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Tempest Therapeutics Inc(Tempest)是一家臨床階段的腫瘤公司。該公司專注於開發結合靶向和免疫介導機制來治療各種腫瘤的療法。該公司的兩個臨床項目為TPST-1495和TPST-1120。 TPST-1120是過氧化物酶體增殖物激活受體的選擇性拮抗劑。TPST-1120正處於實體瘤的I期和 II 期試驗中,包括一項全球隨機Ib/II期試驗,聯合標準一線治療方案atezolizumab和貝伐單抗治療晚期或轉移性肝細胞癌。TPST-1495是EP2和EP4(前列腺素E2受體)的雙重拮抗劑,目前正處於實體瘤的I期單一療法和聯合試驗中。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Petpiboon Prasit | - | - | Acting Chief Scientific Officer & Executive Director |
Michael G. Raab | 58 | 2019 | Independent Chairman |
Drew Mark Pardoll | - | - | Member of Advisory Board |
Benjamin F. Cravatt | 53 | 2019 | Member of Advisory Board |
Jason J. Luke | - | - | Member of Advisory Board |
Geoffrey M. Nichol | 68 | 2021 | Independent Director |
Petpiboon Prasit | - | - | Member of Advisory Board |
Christine A. Pellizzari | 55 | 2021 | Independent Director |
Russell Vance | - | 2021 | Member of Advisory Board |
Toni K. Choueiri | - | - | Member of Advisory Board |
Raymond N. DuBois | 68 | - | Member of Advisory Board |
Ronit Simantov | 58 | 2021 | Independent Director |
Stephen R. Brady | 53 | 2021 | CEO, President & Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核